Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting ...Middle East

ROCKVILLE,M.D. and SUZHOU, China, Nov. 13, 2022 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic,...

Hence then, the article about innovent presents clinical data of phase ia study for ibi351 kras g12c inhibitor as monotherapy for solid tumors at the 2022 chinese society of clinical oncology csco annual meeting was published today ( Monday 14/11/2022 - 03:16 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Innovent Presents Clinical Data of Phase Ia Study for IBI351 (KRAS G12C Inhibitor) as Monotherapy for Solid Tumors at the 2022 Chinese Society of Clinical Oncology (CSCO) Annual Meeting )

Also on site :

• The Lenox Spice Village Trend Is Back, and Macy's ‘Vibrant’ Matching Table Linens Are a ‘Beautiful’ Addition
• Amazon may owe you money: It just got $600 million in tariff refunds after a lawsuit accused it of favoring Trump
• Oscar Mayer Turned a Viral TikTok Trend Into a Real Cake for the Wienermobile's 90th—Here's How to Get It